The Training Resource Package (TRP) for Family Planning’s Progestin-Only Injectable module includes sessions V and VI which are focused on DMPA-SC and self-injection, as well as a number of related handouts and resources. Developed in partnership with the Access Collaborative, these materials are intended for training health care providers who offer progestin-only injectable contraception (“injectables”) in the public or private sector.

The TRP website features training information and materials for a wide range of family planning methods. This includes curriculum components and tools for trainers to design, implement, and evaluate family planning and reproductive health training.

The Family Planning Financing Roadmap is a resource for USAID Mission staff and others working on family planning issues in developing countries. The website is designed to support sustainable family planning approaches for a wide range of users, from those who have very limited knowledge of health financing concepts to those who have some knowledge or experience and are looking to develop a deeper understanding of specific issues. The website has three main sections: learning materials, an interactive roadmap, and a community of practice.

This is an open-access collection of health market literature, featuring documents and related resources needed to understand, develop, and intervene in different global health markets.

This toolkit contains resources designed to help pharmacy associations become effective advocates and begin working to change policies in their countries. The toolkit can be adapted to advocate for any injectable contraceptive. The toolkit includes a Resource for Considering DMPA-SC.

This is a practical reference for global health practitioners working to introduce or scale up medical devices, diagnostics, or other consumer products. Its four-stage model uses case studies to highlight lessons and factors for consideration. Includes a practitioner’s workbook and a toolkit.

This 4-page brief is focused on the use of drug shops to increase access to injectable contraceptives.

To facilitate decision-making around the introduction and scale-up of contraceptive technologies, the Expanding Effective Contraceptive Options (EECO) project, led by WCG Cares in partnership with PSI, and USAID’s Center for Innovation and Impact teamed up to create the Contraceptive Innovation Index. On January 25, 2023, EECO and USAID hosted a webinar on the development and use of this tool; the webinar slides and recording are linked below.

This report presents an in-depth analysis of Burkina Faso’s policies, regulations, and guidelines, based on an extensive document review followed by key informant interviews. The findings are organized by select family planning methods, including voluntary surgical contraception, implants, injectables, and pills. The report also includes a section describing COVID-19’s effect on task sharing and self-care policies. The authors recommend policy and regulatory revisions and actions to further improve the country’s family planning and regulatory environment and scale implementation of the World Health Organization (WHO) guidelines and note that the Burkina Faso experience may serve as evidence when the WHO next updates its task sharing guidance.

In 2018, Zambia initiated a strategy development process to introduce and scale up DMPA-SC, which called for private sector engagement. The purpose of this activity was to generate
experience from a DMPA-SC self-injection pilot in the private sector to inform country and global learning, and to provide the Zambian MOH with operational recommendations for policy and program planning. In partnership with the Zambian Ministry of Health (MOH), we designed and applied a client centered approach that reflected the specific needs and desires of private health sector clients and providers. We adapted and tailored globally available DMPA-SC training materials and methodologies designed largely for a public sector context to a private sector setting. The private sector pilot demonstrated that a shorter training format, that incorporated an e-learning video and individual consultation, was effective for training clients in DMPA-SC self-injection. Based on stakeholder interviews and a highly participatory HCD workshop, we developed and provided the Zambian MOH with recommendations for a phased, targeted DMPA-SC self-injection scale-up based on a total market approach. This activity demonstrated that a shorter DMPA-SC training format was effective for training private providers and their clients in self-injection, and that most women who participated in the pilot are willing to pay a price similar to or higher than the negotiated donor price of $.85 per unit. With only one DMPA-SC product available in the global market, the authors strongly encourage Zambia and other countries committed to engaging the private sector to consider a phased, targeted approach using market segmentation to strengthen public and private sector coordination, minimize product leakage, and ensure quality standardization across all service delivery channels.

Thirty-one years ago, Uniject—a prefilled, single dose syringe and needle package that features a collapsible blister—was conceptualized. Seventeen years later Uniject was approved to administer 104 mg of the contraceptive depot medroxyprogesterone acetate subcutaneously (DMPA-SC). DMPA-SC is still nascent in many countries, but in others it has transitioned to prominence even where there is already an intramuscular DMPA (DMPA-IM) product on the market. DMPASC is now coming of age, and offering it alongside a broad range of other contraceptive options, including fertility awareness methods, long-acting reversible methods, and permanent methods, increases choice and access to voluntary family planning.